Advertisement
Screener

Minerva Neurosciences, Inc. (NERV) Payments to Acquire Held-to-maturity Securities

1.6 / 5 stars · 17/54 Roast Me

Minerva Neurosciences, Inc. Payments to Acquire Held-to-maturity Securities

Minerva Neurosciences, Inc. (NERV) reported Payments to Acquire Held-to-maturity Securities of $40.66 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-12.

Discontinued › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquireHeldToMaturitySecurities · last filed 2019-03-12

  • Minerva Neurosciences, Inc. payments to acquire held-to-maturity securities for fiscal 2018 was $40.66M, a 69.77% decline from fiscal 2017.
  • Minerva Neurosciences, Inc. payments to acquire held-to-maturity securities for fiscal 2017 was $134.53M.
Period endPayments to Acquire Held-to-maturity Securities 12 month
2018-12-31$40.66M
10-K · filed 2019-03-12
2017-12-31$134.53M
10-K · filed 2019-03-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Tonix Pharmaceuticals Holding Corp. (TNXP)United States$0.166B-1.34
ADC Therapeutics SA (ADCT)$0.163B-1.39
LIFECORE BIOMEDICAL, INC. DE (LFCR)United States$0.163B-8.50
Organogenesis Holdings Inc. (ORGO)United States$0.182B-3.70
Annexon, Inc. (ANNX)United States$0.147B-4.22
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
PepGen Inc. (PEPG)United States$0.186B-1.73
Corbus Pharmaceuticals Holdings, Inc. (CRBP)United States$0.144B-1.72
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
Fortress Biotech, Inc. (FBIO)United States$0.188B0.91